Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Hepatocellular Carcinoma

NCT07042919 is registered in ClinicalTrials.gov with Devalingam Mahalingam as lead sponsor.

NCT NCT07042919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07042919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Hepatocellular Carcinoma
Lead sponsor
Devalingam Mahalingam
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 30, 2026
Completion date
March 4, 2031
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, cirrhosis, stage iii hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8